2-(3-Aminophenyl)-2-methylpropanenitrile - CAS 915394-29-5
Catalog: |
BB061406 |
Product Name: |
2-(3-Aminophenyl)-2-methylpropanenitrile |
CAS: |
915394-29-5 |
Synonyms: |
3-Amino-α,α-dimethylbenzeneacetonitrile; 3-(Cyanodimethylmethyl)phenylamine |
IUPAC Name: | 2-(3-aminophenyl)-2-methylpropanenitrile |
Description: | 2-(3-Aminophenyl)-2-methylpropanenitrile |
Molecular Weight: | 160.22 |
Molecular Formula: | C10H12N2 |
Canonical SMILES: | CC(C)(C#N)C1=CC(=CC=C1)N |
InChI: | InChI=1S/C10H12N2/c1-10(2,7-11)8-4-3-5-9(12)6-8/h3-6H,12H2,1-2H3 |
InChI Key: | HNABISIMXKEHQF-UHFFFAOYSA-N |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2021067682-A1 | Tricyclic kinase inhibitors and uses thereof | 20191003 |
AU-2019417418-A1 | (pyridin-2-yl)amine derivatives as ΤGFβR1 R1 (Alk5) inhibitors for the treatment of cancer | 20181227 |
TW-202039436-A | Inhibitors of tgf-beta r1 (alk5) useful to treat cell proliferation disorders | 20181227 |
WO-2020139636-A1 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | 20181227 |
BR-112021007006-A2 | (pyridin-2-yl)amine derivatives as tgf-beta r1(alk5) inhibitors for cancer treatment | 20181227 |
CN-113348167-A | (pyridin-2-yl) amine derivatives as TGF-beta R1(ALK5) inhibitors for the treatment of cancer | 20181227 |
KR-20210110316-A | (pyridin-2-yl)amine derivatives as TGF-beta R1 (ALK5) inhibitors for the treatment of cancer | 20181227 |
EP-3902796-A1 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | 20181227 |
JP-2022517730-A | (Pyridine-2-yl) amine derivative as a TGF-beta R1 (ALK5) inhibitor for the treatment of cancer | 20181227 |
US-2022054465-A1 | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer | 20181227 |
Complexity: | 199 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 160.100048391 |
Formal Charge: | 0 |
Heavy Atom Count: | 12 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 160.100048391 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 49.8Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 2 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS